Portola Pharmaceuticals (NASDAQ:PTLA) has been assigned an average recommendation of “Hold” from the ten research firms that are covering the company, Marketbeat Ratings reports. Two equities research analysts have rated the stock with a sell rating, two have assigned a hold rating and six have issued a buy rating on the company. The average 1-year price target among brokerages that have issued a report on the stock in the last year is $66.60.
Several research firms have weighed in on PTLA. Zacks Investment Research raised Portola Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Saturday, April 7th. ValuEngine raised Portola Pharmaceuticals from a “strong sell” rating to a “sell” rating in a report on Monday, April 2nd. Oppenheimer reaffirmed a “buy” rating on shares of Portola Pharmaceuticals in a report on Wednesday, March 21st. BidaskClub cut Portola Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Wednesday, March 21st. Finally, William Blair reaffirmed a “buy” rating on shares of Portola Pharmaceuticals in a report on Tuesday, March 13th.
In other news, EVP Tao Fu sold 1,135 shares of the stock in a transaction dated Monday, March 12th. The stock was sold at an average price of $38.47, for a total transaction of $43,663.45. Following the transaction, the executive vice president now directly owns 18,346 shares in the company, valued at approximately $705,770.62. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. 5.50% of the stock is currently owned by corporate insiders.
Institutional investors have recently made changes to their positions in the company. Oppenheimer Asset Management Inc. increased its position in shares of Portola Pharmaceuticals by 251.2% during the 3rd quarter. Oppenheimer Asset Management Inc. now owns 2,862 shares of the biopharmaceutical company’s stock valued at $155,000 after purchasing an additional 2,047 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank grew its position in Portola Pharmaceuticals by 54.9% during the 4th quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 3,219 shares of the biopharmaceutical company’s stock worth $157,000 after acquiring an additional 1,141 shares during the last quarter. Sei Investments Co. bought a new position in Portola Pharmaceuticals during the 3rd quarter worth approximately $217,000. Cubist Systematic Strategies LLC bought a new position in Portola Pharmaceuticals during the 3rd quarter worth approximately $218,000. Finally, Penbrook Management LLC bought a new position in Portola Pharmaceuticals during the 4th quarter worth approximately $209,000. Hedge funds and other institutional investors own 88.43% of the company’s stock.
Shares of NASDAQ:PTLA traded down $0.37 on Thursday, hitting $32.98. The company’s stock had a trading volume of 834,782 shares, compared to its average volume of 1,169,038. Portola Pharmaceuticals has a 1 year low of $30.10 and a 1 year high of $67.10. The stock has a market cap of $2,218.85, a P/E ratio of -6.86 and a beta of 1.49. The company has a quick ratio of 5.92, a current ratio of 5.94 and a debt-to-equity ratio of 0.30.
Portola Pharmaceuticals (NASDAQ:PTLA) last released its quarterly earnings results on Wednesday, February 28th. The biopharmaceutical company reported ($1.41) earnings per share for the quarter, beating the consensus estimate of ($1.46) by $0.05. Portola Pharmaceuticals had a negative return on equity of 108.43% and a negative net margin of 1,268.34%. The firm had revenue of $9.80 million for the quarter, compared to analysts’ expectations of $3.71 million. During the same quarter last year, the firm posted ($0.95) EPS. The company’s revenue was down 28.4% compared to the same quarter last year. equities research analysts expect that Portola Pharmaceuticals will post -5.06 EPS for the current fiscal year.
Portola Pharmaceuticals Company Profile
Portola Pharmaceuticals, Inc, a biopharmaceutical company, develops and commercializes therapeutics in the areas of thrombosis, other hematologic disorders, and inflammation. The company is developing Betrixaban, an oral once-daily Factor Xa inhibitor for hospital and extended duration prophylaxis of venous thromboembolism in adults hospitalized for an acute medical illness; Andexanet alfa, a recombinant protein that is in Phase III study for reverse anticoagulant activity in patients treated with fXa inhibitor; and Cerdulatinib, a spleen tyrosine kinase inhibitor, which is in Phase IIa clinical stage to treat hematologic cancers.
Receive News & Ratings for Portola Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Portola Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.